vimarsana.com

While Doing Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial | Critical Care Medicine | JAMA

This randomized clinical trial examines the effect of initiation of a renin-angiotensin system inhibitor (ACE inhibitor or an angiotensin receptor blocker) on t

Eteläuomen läiSaudi arabiaSri lankaUniversity of minnesotaUnited statesSan franciscoNew south walesCity ofUnited kingdomKrung thep mahanakhonBritish columbiaFrance generalNew zealandWestern australiaNorthern irelandSouth australia

Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19

This exploratory study of a multiplatform randomized trial investigating the effects of therapeutic-dose heparin in early-pandemic hospitalized COVID-19 patient

United statesNew zealandProvince of ontarioWestern australiaBruxelles capitaleChristopher seymourMonte carloMeredian bioEwanc goligherLyonelg israels researchMultifactorial adaptive platform trial for communityGlobal coalition for adaptive researchUniversity of marylandBoehringer ingelheimAustralian national healthAmag pharmaceuticals

Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial | Critical Care Medicine | JAMA

This secondary analysis of an ongoing adaptive platform trial examines the effect of multiple interventions for critically ill adults with COVID-19 on longer-te

United kingdomSouth australiaFrance generalCity ofBritish columbiaUnited statesWestern australiaSan franciscoNew zealand generalNew zealandEstado de pernambucoNational universityEteläuomen läiSao pauloSri lankaAr riya

Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial | Critical Care Medicine | JAMA

This randomized clinical trial assesses the effect of treatment with an antiplatelet agent vs no antiplatelet therapy on days alive and free of intensive care u

Nordrhein westfalenCity ofUnited kingdomFrance generalBritish columbiaUnited statesBedford parkSouth australiaFlinders universityWestern australiaSan franciscoNew zealand generalNew zealandEstado de pernambucoNational university of singaporeSingapore general

Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non–Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial | Anticoagulation | JAMA

This randomized clinical trial evaluates the benefits and risks of the addition of a P2Y12 inhibitor to anticoagulant therapy compared with anticoagulant therap

New yorkUnited statesProvince of ontarioEspero biopharmaBoehringer ingleheimNigro maiaDaiichi sankyoOliveira antunesLopez sendon morenoBaumann kreuzigerBoeringher ingleheimJeffreys bergerCorrona pharmacovigilanceCerus corpAbbott vascular incSunovion pharmaceuticals

vimarsana © 2020. All Rights Reserved.